AC Immune (NASDAQ:ACIU) Stock Has Consensus Price Target of $7.50

AC Immune (NASDAQ:ACIU) has earned an average rating of “Hold” from the five research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.50.

Several equities analysts have commented on the stock. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. HC Wainwright restated a “buy” rating on shares of AC Immune in a research note on Thursday, September 24th. Zacks Research lowered shares of AC Immune from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 28th. Finally, BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Wednesday, September 23rd.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $2.22 on Monday. The stock has a market cap of $225.94 million, a PE ratio of -4.11 and a beta of 1.56. The business has a 50 day moving average of $2.61 and a 200-day moving average of $2.73. AC Immune has a 12-month low of $2.03 and a 12-month high of $3.90.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.13. The business had revenue of $18.67 million during the quarter, compared to analysts’ expectations of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. Equities research analysts expect that AC Immune will post -0.60 earnings per share for the current year.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently added to or reduced their stakes in the stock. AXQ Capital LP bought a new stake in shares of AC Immune in the 2nd quarter worth about $25,000. Dimensional Fund Advisors LP increased its holdings in shares of AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after acquiring an additional 30,035 shares in the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.